Home / Business / Alzheimer’s drug aducanumab sparks emotional battle as FDA nears deadline on whether to approve it

Alzheimer’s drug aducanumab sparks emotional battle as FDA nears deadline on whether to approve it



But intravenous administration does not cure Alzheimer’s disease or reverse it. Drug analysts say it could have a price tag of up to $50,000 a year per patient. by adding billions of dollars to the nation’s health tab. And it depends on how the FDA labels it. Millions of people may be eligible for the drug. or at least for assessing whether or not they should take this drug. experts say


Source link